Personalised cell therapy - Adaptive Biotechnologies
Latest Information Update: 24 Feb 2024
At a glance
- Originator Adaptive Biotechnologies; Fred Hutchinson Cancer Research Center
- Developer Adaptive Biotechnologies; Genentech
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer